
Cognito Therapeutics
Using visual and auditory stimulation to treat neurodegenerative disorders.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor | €0.0 | round | |
investor investor investor investor investor | €0.0 | round | |
* | N/A | $35.0m Valuation: $365m | Series B |
Total Funding | 000k |
Related Content
Cognito Therapeutics is a medical technology startup that operates in the healthcare sector, specifically focusing on neurodegenerative diseases such as Alzheimer's. The company's mission is to improve the lives of patients suffering from these diseases through the development of novel therapeutics.
The company's primary offering is a breakthrough medical device that delivers non-invasive neuromodulation treatment. Neuromodulation is a process that alters nerve activity through the delivery of electrical or pharmaceutical agents directly to a target area. This device has the potential to significantly improve outcomes for patients with neurodegenerative diseases, offering a new hope for treatment.
Cognito's business model revolves around the research, development, and commercialization of this proprietary technology. The company's target market includes millions of patients worldwide suffering from neurodegenerative diseases, as well as healthcare providers seeking innovative treatment options.
The company generates revenue through the sale of its medical devices and related services. It also stands to benefit from potential partnerships with larger medical device companies and healthcare institutions, as well as from grants and funding for medical research and development.
In summary, Cognito Therapeutics is a promising startup in the MedTech space, offering a novel approach to treating neurodegenerative diseases. Its innovative technology and strong leadership team position it well for future growth in the healthcare sector.
Keywords: Neurodegenerative Diseases, Alzheimer's, Medical Technology, Neuromodulation, Non-Invasive Treatment, Healthcare Sector, Medical Device, Research and Development, Proprietary Technology, Patient Outcomes.